Global Encephalitis Treatment Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Encephalitis Treatment Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032

Global Encephalitis Treatment Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 – 2032

Global Encephalitis Treatment Market was valued at US $20.5 Billion in 2022 and is expected to reach ~US $33 Billion by 2032, growing at a CAGR of 4.8% during the forecast period 2023-2032.

Encephalitis is a serious condition characterized by inflammation of the brain. The inflammation can cause a wide range of neurological symptoms and, depending on the cause and severity, can be life-threatening. It usually results from infections brought on by bacteria or viruses, though occasionally immune system malfunctions are also to blame. Many physical and neurological symptoms, such as fever, headaches, stiffness in the muscles, weakness, abnormal behaviour, confusion, memory loss, seizures, increased sensitivity to light, and even loss of consciousness, can be signs of encephalitis. Since encephalitis can have serious effects for the affected person, prompt and correct diagnosis and treatment are essential. Early diagnosis and treatment are crucial for managing the condition and preventing complications.

The severity of encephalitis symptoms might vary, which highlights the necessity of receiving treatment right away. Medications such as antiviral treatments, steroids, antibiotics, immunoglobulin therapy, plasmapheresis, and antifungal and anticonvulsant medications are commonly used to treat encephalitis. Because encephalitis has high rates of death and morbidity, it is a global health concern. Reducing mortality rates globally requires addressing such diseases. Despite improvements in treatment options, the National Institutes of Health reports that the yearly global incidence of encephalitis ranges from 3.5 to 7.4 cases per 100,000 people. Additionally, research from the same organisation shows that 5–20% of those who contract encephalitis die from it.

The increased mortality and morbidity rates linked to encephalitis virus infections are the main driver of the market's expansion. The market also gains from more government campaigns to promote immunisation programs. As an illustration, as of April 28, 2022, the World Health Organisation had documented 37 instances of Japanese encephalitis in humans across four states in Australia, consisting of 12 suspected cases and 25 laboratory-confirmed cases. People are becoming more likely to adopt preventive actions, including immunisation, as the number of cases and fatalities rises. The market is expanding due to the increased need for encephalitis treatments. Additionally, it is anticipated that the rising incidence of cancer will play a major role in driving market expansion. Certain immune system diseases can cause encephalitis when the body is fighting cancer, which increases the incidence of encephalitis.

“Antiviral agents segment, by treatment type, to be dominating market from 2023 to 2030.”

The market for encephalitis treatments worldwide is divided into segments based on the type of treatment used, which includes immunoglobulin therapy, steroids, antibiotics, antiviral drugs, plasmapheresis, and other methods. The antiviral agent category became the biggest contributor in 2022. These antiviral medications play a critical role in the treatment of primary encephalitis caused by a variety of viruses. The rising incidence of primary encephalitis caused by different viruses, which is driving demand for antiviral agents, the rise in awareness and diagnosis of encephalitis cases, and the fact that antiviral agents are a more affordable treatment option than some other modalities, which makes them accessible to a wider patient population, are some of the factors that support the dominance of the antiviral agent segment.

“Oral segment, by route of administration, to be dominating market from 2023 to 2030.”

The mode of administration—oral, parenteral, and other—determines the market segmentation for encephalitis treatments. With the biggest market share, the oral segment became the most dominating category in 2022. The oral mode of administration is frequently used for treating encephalitis due to its efficaciousness in delivering medication to patients, which is one of the causes contributing to this segment's dominance. Because oral administration does not require injections or other intrusive procedures, it is a non-invasive strategy that is preferred by both patients and healthcare practitioners. To further reinforce their position as the first choice for treating encephalitis, oral drugs are also renowned for being easy to administer, store, and carry around.

“North America to be largest region in Encephalitis Treatment Market.”

The encephalitis treatment market is segmented into four regions: North America, Europe, Asia-Pacific, and Others. Others are split up into South America and the Middle East.

In terms of revenue, North America led the encephalitis treatment market in 2022. This leadership status can be ascribed to multiple variables, such as an elevated prevalence of encephalitis, augmented spending in research and development aimed at creating novel medications to treat encephalitis, prominent industry participants, and a firmly developed healthcare infrastructure. It is anticipated that the North American market would experience strong expansion, propelled by continuous improvements in the healthcare sector and bolstered by heightened industry research and development endeavours. Over the course of the forecast period, the region is anticipated to attain the highest CAGR of 5.2%.

The yearly incidence of encephalitis is estimated to be between 10 and 15 cases per 100,000 individuals; during the last ten years, over 250,000 cases have been reported in the US. Although encephalitis can strike people at any age, it most frequently strikes children and teenagers. Roughly 15% of instances of encephalitis are associated with HIV infection. During the past ten years, there has been a notable increase in the prevalence of encephalitis in children in the United States. The increased use of immunosuppressive treatments, as well as bone marrow and solid organ transplantation, which are linked to an increased risk of encephalitis, may be partially to blame for this rise. Moreover, the increased identification of encephalitis cases might have been facilitated by the enhanced sensitivity of magnetic resonance imaging (MRI) for brain parenchymal imaging.

Over the course of the forecast period, the Asia Pacific encephalitis treatment market is expected to grow at a steady pace, with a compound annual growth rate (CAGR) of 5.1%. The market for encephalitis treatments is dominated by this area, which is notable for having nations like South Korea, China, and India. The large number of elderly people and the rising disease prevalence are the main causes of this dominance. As to the March 2022 updates provided by the European Centre for Disease Prevention and Control, the Japanese Encephalitis virus is widespread throughout Asia and Oceania, extending from Japan to India, Pakistan, and Australia. There will likely be more patients as a result of the healthcare sector's ongoing expansion and the growing older population in these economies. India, China, and Brazil in particular are expected to become fast expanding markets as a result of increased government spending on bettering healthcare facilities and infrastructure.

Encephalitis Treatment Competitive Landscape

The competitive landscape of the Encephalitis Treatment Market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats of the industry. Key industry players have recognized that the adoption of Encephalitis Treatment technology holds the potential for further growth. The growing desire among producers to optimize their production costs has spurred collaborative efforts among companies to scale up their production capacity. This strategic collaboration not only aims to increase revenue but also seeks to establish dominance in the market.

The Encephalitis Treatment Market is highly competitive, with numerous companies vying for market share. Prominent companies in the Encephalitis Treatment Market include:

Major Players:

Allergan

Merck & Co., Inc.

Pfizer Inc.

GlaxoSmithKline plc

Melinta Therapeutics LLC

Basilea Pharmaceutica Ltd.

Abbott

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Sanofi

Recent Developments:

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) released a positive opinion in December 2022, suggesting that Dupixent (dupilumab) be approved in the EU for the treatment of eosinophilic oesophagitis (EoE) in adults and adolescents.

The U.S. Food and Drug Administration (FDA) authorised Dupixent 300 mg once a week in May 2022 for the treatment of patients who weighed at least 40 kg and were 12 years of age or older.

Pfizer Inc. declared in February 2021 that the Biologics License Application (BLA) for TicoVac, a vaccine against tick-borne encephalitis (TBE) meant for active immunisation to prevent TBE in people one year of age and older, had been accepted by the U.S. Food and Drug Administration (FDA). Neutralising antibodies against the wild-type TBE virus can be produced via TICOVAC. It contains albumin, a substance produced from human blood. There is a very low chance of both viral sickness and variant Creutzfeldt-Jakob disease (vCJD) spreading because of strict donor screening and product production protocols.